{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:26Z","timestamp":1790742686755,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,23]]},"DOI":"10.7759\/cureus.81023","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T05:13:27Z","timestamp":1742706807000},"source":"Crossref","is-referenced-by-count":4,"title":["Global Economic Burden of Spinal Muscular Atrophy: A Systematic Literature Review"],"prefix":"10.7759","author":[{"given":"Rawda","family":"Elshahawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher","family":"Elezbawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Ashmawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Elshahawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosra S","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Korra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana A","family":"Al-Abdulkarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain  A","family":"Al-Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Dallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad N","family":"Fasseeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Organization for Rare Disorders. Spinal muscular atrophy-symptoms, causes, treatment. (2022). Accessed. January 17, 2025: https:\/\/rarediseases.org\/rare-diseases\/spinal-muscular-atrophy\/."},{"key":"ref2","unstructured":"NHS. Spinal muscular atrophy (SMA). (2024). Accessed. January 17, 2025: https:\/\/www.nhs.uk\/conditions\/spinal-muscular-atrophy-sma\/."},{"key":"ref3","unstructured":"EURORDIS. Spinal muscular atrophy. (2009). Accessed. January 18, 2025: https:\/\/www.eurordis.org\/stories\/spinal-muscular-atrophy\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy-a literature review","volume":"12","author":"Verhaart IE","year":"2017","unstructured":"Verhaart IE, Robertson A, Wilson IJ, et al.. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy-a literature review. Orphanet J Rare Dis. 2017, 12:124. 10.1186\/s13023-017-0671-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri E","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022, 8:52. 10.1038\/s41572-022-00380-8","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01548-5","article-title":"Significant healthcare burden and life cost of spinal muscular atrophy: real-world data","volume":"24","author":"Chan SH","year":"2023","unstructured":"Chan SH, Wong CK, Wu T, Wong W, Yu MK, Au IC, Chan GC. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. Eur J Health Econ. 2023, 24:1373-82. 10.1007\/s10198-022-01548-5","journal-title":"Eur J Health Econ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/fnl.13.58","article-title":"Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond","volume":"9","author":"Monani UR","year":"2014","unstructured":"Monani UR, De Vivo DC. Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol. 2014, 9:49-65. 10.2217\/fnl.13.58","journal-title":"Future Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01200.x","article-title":"Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling","volume":"76","author":"Rudnik-Sch\u00f6neborn S","year":"2009","unstructured":"Rudnik-Sch\u00f6neborn S, Berg C, Zerres K, et al.. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009, 76:168-78. 10.1111\/j.1399-0004.2009.01200.x","journal-title":"Clin Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/ejpn.1999.0181","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz V","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999, 3:49-51. 10.1053\/ejpn.1999.0181","journal-title":"Eur J Paediatr Neurol"},{"key":"ref10","unstructured":"Spinal muscular atrophy (SMA). Accessed. January 18, 2025: https:\/\/my.clevelandclinic.org\/health\/diseases\/14505-spinal-muscular-atrophy-sma."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1366943","article-title":"Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies","volume":"12","author":"Lagae L","year":"2024","unstructured":"Lagae L, Proesmans M, Van den Hauwe M, Vermeulen F, De Waele L, Boon M. Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies. Front Pediatr. 2024, 12:1366943. 10.3389\/fped.2024.1366943","journal-title":"Front Pediatr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100346","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow H","year":"2021","unstructured":"Chaytow H, Faller KM, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021, 2:100346. 10.1016\/j.xcrm.2021.100346","journal-title":"Cell Rep Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2","article-title":"Costs of illness of spinal muscular atrophy: a systematic review","volume":"19","author":"Landfeldt E","year":"2021","unstructured":"Landfeldt E, Pechmann A, McMillan HJ, Lochm\u00fcller H, Sejersen T. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021, 19:501-20. 10.1007\/s40258-020-00624-2","journal-title":"Appl Health Econ Health Policy"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1339-3","article-title":"Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review","volume":"15","author":"Wan HW","year":"2020","unstructured":"Wan HW, Carey KA, D'Silva A, Vucic S, Kiernan MC, Kasparian NA, Farrar MA. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis. 2020, 15:70. 10.1186\/s13023-020-1339-3","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01115-5","article-title":"Systematic literature review to identify utility values in patients with spinal muscular atrophy (SMA) and their caregivers","volume":"40","author":"Sutherland CS","year":"2022","unstructured":"Sutherland CS, Hudson P, Mitchell S, Paracha N. Systematic literature review to identify utility values in patients with spinal muscular atrophy (SMA) and their caregivers. Pharmacoeconomics. 2022, 40:39-67. 10.1007\/s40273-021-01115-5","journal-title":"Pharmacoeconomics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01105-7","article-title":"Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management","volume":"40","author":"Paracha N","year":"2022","unstructured":"Paracha N, Hudson P, Mitchell S, Sutherland CS. Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management. Pharmacoeconomics. 2022, 40:11-38. 10.1007\/s40273-021-01105-7","journal-title":"Pharmacoeconomics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02089-2","article-title":"Systematic literature review of clinical and economic evidence for spinal muscular atrophy","volume":"39","author":"Yang M","year":"2022","unstructured":"Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, Igarashi A. Systematic literature review of clinical and economic evidence for spinal muscular atrophy. Adv Ther. 2022, 39:1915-58. 10.1007\/s12325-022-02089-2","journal-title":"Adv Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02407-5","article-title":"Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs","volume":"17","author":"Brandt M","year":"2022","unstructured":"Brandt M, Johannsen L, Inhestern L, Bergelt C. Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs. Orphanet J Rare Dis. 2022, 17:274. 10.1186\/s13023-022-02407-5","journal-title":"Orphanet J Rare Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff T","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021, 16:47. 10.1186\/s13023-021-01695-7","journal-title":"Orphanet J Rare Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01197-9","article-title":"Caregiver burden of spinal muscular atrophy: a systematic review","volume":"41","author":"Landfeldt E","year":"2023","unstructured":"Landfeldt E, Abner S, Pechmann A, Sejersen T, McMillan HJ, Lochm\u00fcller H, Kirschner J. Caregiver burden of spinal muscular atrophy: a systematic review. Pharmacoeconomics. 2023, 41:275-93. 10.1007\/s40273-022-01197-9","journal-title":"Pharmacoeconomics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0152","article-title":"Modern burden of disease studies as a basis for decision-making processes in public health","volume":"118","author":"Karch A","year":"2021","unstructured":"Karch A. Modern burden of disease studies as a basis for decision-making processes in public health. Dtsch Arztebl Int. 2021, 118:135-6. 10.3238\/arztebl.m2021.0152","journal-title":"Dtsch Arztebl Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb SJ","year":"2011","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011, 68:979-84. 10.1001\/archneurol.2011.74","journal-title":"Arch Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio H","year":"2023","unstructured":"Nishio H, Niba ET, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023, 24:11939. 10.3390\/ijms241511939","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/S13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:10.1186\/S13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref26","unstructured":"ISPOR. Economic evaluation. Accessed. February 18, 2025: https:\/\/www.ispor.org\/heor-resources\/good-practices\/economic-evaluation."},{"key":"ref27","unstructured":"Inflation, consumer prices (annual %). Accessed. January 18, 2025: https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL.ZG."},{"key":"ref28","unstructured":"Official exchange rate (LCU per US$, period average). Accessed. January 18, 2025: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1057\/9781137275677_3","article-title":"Absenteeism and presenteeism","author":"Quazi H","year":"2013","unstructured":"Quazi H. Absenteeism and presenteeism. Presenteeism: The Invisible Cost to Organizations. Palgrave Macmillan, London; 2013. 31-44. 10.1057\/9781137275677_3"},{"key":"ref30","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed. January 18, 2025: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref31","unstructured":"Newcastle-Ottawa Scale-an overview. Accessed. January 18, 2025: http:\/\/www.sciencedirect.com\/topics\/nursing-and-health-professions\/newcastle-ottawa-scale\/."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.1.53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman JJ","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay JW. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003, 9:53-61. 10.18553\/jmcp.2003.9.1.53","journal-title":"J Manag Care Pharm"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2019-000572","article-title":"Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review","volume":"3","author":"Ali I","year":"2019","unstructured":"Ali I, Gilchrist FJ, Carroll WD, et al.. Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review. BMJ Paediatr Open. 2019, 3:e000572. 10.1136\/bmjpo-2019-000572","journal-title":"BMJ Paediatr Open"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy S","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, et al.. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019, 54:179-85. 10.1002\/ppul.24203","journal-title":"Pediatr Pulmonol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.093","article-title":"PBI10 type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen","volume":"22","author":"Arjunji R","year":"2019","unstructured":"Arjunji R, Dean R, Jensen IS, et al.. PBI10 type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen. Value Health. 2019, 22:S48. 10.1016\/j.jval.2019.04.093","journal-title":"Value Health"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1198355","article-title":"The economic burden of spinal muscular atrophy","volume":"19","author":"Armstrong EP","year":"2016","unstructured":"Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ. 2016, 19:822-6. 10.1080\/13696998.2016.1198355","journal-title":"J Med Econ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.21115\/JBES.v13.n2.p94-107","article-title":"Healthcare resource utilization of spinal muscular atrophy in the Brazilian Unified Health System: a retrospective database study","volume":"13","author":"Barbour J","year":"2021","unstructured":"Barbour J, Ara\u00fajo AP, Zanoteli E, et al.. Healthcare resource utilization of spinal muscular atrophy in the Brazilian Unified Health System: a retrospective database study. J Bras Econ Sa\u00fade. 2021, 13:94-107. 10.21115\/JBES.v13.n2.p94-107","journal-title":"J Bras Econ Sa\u00fade"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0","article-title":"Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain","volume":"12","author":"L\u00f3pez-Bastida J","year":"2017","unstructured":"L\u00f3pez-Bastida J, Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017, 12:141. 10.1186\/s13023-017-0695-0","journal-title":"Orphanet J Rare Dis"},{"key":"ref39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.09.2374","article-title":"PRO44 the economic impact and health-related quality of life of spinal muscular atrophy (SMA). An analysis across three European countries","volume":"22","author":"Lopez Bastida J","year":"2019","unstructured":"Lopez Bastida J, Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E. PRO44 the economic impact and health-related quality of life of spinal muscular atrophy (SMA). An analysis across three European countries. Value Health. 2019, 22:S848-9.","journal-title":"Value Health"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0455-8","article-title":"Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen","volume":"21","author":"Beauchamp KA","year":"2019","unstructured":"Beauchamp KA, Johansen Taber KA, Muzzey D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genet Med. 2019, 21:1948-57. 10.1038\/s41436-019-0455-8","journal-title":"Genet Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1843277","article-title":"Economic burden of spinal muscular atrophy: an analysis of claims data","volume":"8","author":"Belter L","year":"2020","unstructured":"Belter L, Cruz R, Kulas S, McGinnis E, Dabbous O, Jarecki J. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020, 8:1843277. 10.1080\/20016689.2020.1843277","journal-title":"J Mark Access Health Policy"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/pan.13500","article-title":"A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen","volume":"28","author":"Bielsky AR","year":"2018","unstructured":"Bielsky AR, Fuhr PG, Parsons JA, Yaster M. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen. Paediatr Anaesth. 2018, 28:1105-8. 10.1111\/pan.13500","journal-title":"Paediatr Anaesth"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen CL","year":"2014","unstructured":"Bladen CL, Thompson R, Jackson JM, et al.. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014, 261:152-63. 10.1007\/s00415-013-7154-1","journal-title":"J Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.09.021","article-title":"Early cost-effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in The Netherlands with relapse scenarios","volume":"24","author":"Broekhoff TF","year":"2021","unstructured":"Broekhoff TF, Sweegers CC, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HG, Goettsch WG, Vreman RA. Early cost-effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in The Netherlands with relapse scenarios. Value Health. 2021, 24:759-69. 10.1016\/j.jval.2020.09.021","journal-title":"Value Health"},{"key":"ref45","article-title":"CADTH: CADTH Common Drug Reviews. In: Pharmacoeconomic Review Report (Resubmission): NUSINERSEN (SPINRAZA): (Biogen Canada Inc.): Indication: Treatment of patients with 5q spinal muscular atrophy","author":"CADTH","year":"2019","unstructured":"CADTH. Pharmacoeconomic Review Report (Resubmission): NUSINERSEN (SPINRAZA): (Biogen Canada Inc.): Indication: Treatment of Patients With 5q Spinal Muscular Atrophy. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2019. http:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0576-spinraza-resubmission-pharmacoeconomic-report.pdf."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-018-0093-0","article-title":"High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the Kids' Inpatient Database (KID)","volume":"3","author":"Cardenas J","year":"2019","unstructured":"Cardenas J, Menier M, Heitzer MD, Sproule DM. High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the Kids' Inpatient Database (KID). Pharmacoecon Open. 2019, 3:205-13. 10.1007\/s41669-018-0093-0","journal-title":"Pharmacoecon Open"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009715","article-title":"Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy","volume":"95","author":"Chambers GM","year":"2020","unstructured":"Chambers GM, Settumba SN, Carey KA, Cairns A, Menezes MP, Ryan M, Farrar MA. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020, 95:e1-10. 10.1212\/WNL.0000000000009715","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2020.09.002","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience","volume":"39","author":"Chen KA","year":"2021","unstructured":"Chen KA, Widger J, Teng A, Fitzgerald DA, D'Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience. Paediatr Respir Rev. 2021, 39:54-60. 10.1016\/j.prrv.2020.09.002","journal-title":"Paediatr Respir Rev"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2013676","article-title":"Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada","volume":"24","author":"Chen G","year":"2021","unstructured":"Chen G, Sharif B, Gerber B, et al.. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. J Med Econ. 2021, 24:51-9. 10.1080\/13696998.2021.2013676","journal-title":"J Med Econ"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.02.011","article-title":"Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy","volume":"29","author":"Cremers CH","year":"2019","unstructured":"Cremers CH, Fischer MJ, Kruitwagen-van Reenen ET, et al.. Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy. Neuromuscul Disord. 2019, 29:321-9. 10.1016\/j.nmd.2019.02.011","journal-title":"Neuromuscul Disord"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1697","article-title":"PSY38-Economic burden of infant-onset (type 1) spinal muscular atrophy: a retrospective claims database analysis","volume":"21","author":"Dabbous O","year":"2018","unstructured":"Dabbous O, Seda J, Sproule DM. PSY38-Economic burden of infant-onset (type 1) spinal muscular atrophy: a retrospective claims database analysis. Value Health. 2018, 21:S251. 10.1016\/j.jval.2018.04.1697","journal-title":"Value Health"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031271","article-title":"Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis","volume":"9","author":"Darb\u00e0 J","year":"2019","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ Open. 2019, 9:e031271. 10.1136\/bmjopen-2019-031271","journal-title":"BMJ Open"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00897-4","article-title":"Direct medical costs of spinal muscular atrophy in the Catalonia region: a population-based analysis","volume":"40","author":"Darb\u00e0 J","year":"2020","unstructured":"Darb\u00e0 J. Direct medical costs of spinal muscular atrophy in the Catalonia region: a population-based analysis. Clin Drug Investig. 2020, 40:335-41. 10.1007\/s40261-020-00897-4","journal-title":"Clin Drug Investig"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1287-y","article-title":"Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis","volume":"15","author":"Darb\u00e0 J","year":"2020","unstructured":"Darb\u00e0 J. Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis. Orphanet J Rare Dis. 2020, 15:8. 10.1186\/s13023-019-1287-y","journal-title":"Orphanet J Rare Dis"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1889841","article-title":"An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)","volume":"9","author":"Dean R","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al.. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021, 9:1889841. 10.1080\/20016689.2021.1889841","journal-title":"J Mark Access Health Policy"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1646263","article-title":"Economic burden of spinal muscular atrophy in the United States: a contemporary assessment","volume":"23","author":"Droege M","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020, 23:70-9. 10.1080\/13696998.2019.1646263","journal-title":"J Med Econ"},{"key":"ref57","article-title":"PND13 burden of illness of spinal muscular atrophy: an update","volume":"22","author":"Droege M","year":"2020","unstructured":"Droege M, Dabbous O, Arjunji R, Gauthier-Loiselle M, Cloutier M, Sproule DM. PND13 burden of illness of spinal muscular atrophy: an update. Value Health Reg Issues. 2020, 22:S76-7.","journal-title":"Value Health Reg Issues"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar MA","year":"2018","unstructured":"Farrar MA, Carey KA, Paguinto SG, Chambers G, Kasparian NA. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open. 2018, 8:e020907. 10.1136\/bmjopen-2017-020907","journal-title":"BMJ Open"},{"key":"ref59","article-title":"Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy [Thesis]","author":"Fox DA","year":"2020","unstructured":"Fox DA. Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy [Thesis]. University of Washington, 2020."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951514000042","article-title":"Palliative care in children with spinal muscular atrophy type I: what do they need?","volume":"13","author":"Garc\u00eda-Salido A","year":"2015","unstructured":"Garc\u00eda-Salido A, de Paso-Mora MG, Monle\u00f3n-Luque M, Martino-Alba R. Palliative care in children with spinal muscular atrophy type I: what do they need?. Palliat Support Care. 2015, 13:313-7. 10.1017\/S1478951514000042","journal-title":"Palliat Support Care"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01938-w","article-title":"Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis","volume":"38","author":"Gauthier-Loiselle M","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, et al.. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021, 38:5809-28. 10.1007\/s12325-021-01938-w","journal-title":"Adv Ther"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.06.007","article-title":"Continuous noninvasive ventilatory support outcomes for patients with neuromuscular disease: a multicenter data collaboration","volume":"27","author":"Gon\u00e7alves MR","year":"2021","unstructured":"Gon\u00e7alves MR, Bach JR, Ishikawa Y, Saporito L, Winck JC. Continuous noninvasive ventilatory support outcomes for patients with neuromuscular disease: a multicenter data collaboration. Pulmonology. 2021, 27:509-17. 10.1016\/j.pulmoe.2021.06.007","journal-title":"Pulmonology"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122346","article-title":"Home mechanical ventilation in childhood-onset hereditary neuromuscular diseases: 13 years' experience at a single center in Korea","volume":"10","author":"Han YJ","year":"2015","unstructured":"Han YJ, Park JD, Lee B, Choi YH, Suh DI, Lim BC, Chae JH. Home mechanical ventilation in childhood-onset hereditary neuromuscular diseases: 13 years' experience at a single center in Korea. PLoS One. 2015, 10:e0122346. 10.1371\/journal.pone.0122346","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00004","article-title":"Palliative care in SMA type 1: a prospective multicenter French study based on parents' reports","volume":"8","author":"Hully M","year":"2020","unstructured":"Hully M, Barnerias C, Chabalier D, et al.. Palliative care in SMA type 1: a prospective multicenter French study based on parents' reports. Front Pediatr. 2020, 8:4. 10.3389\/fped.2020.00004","journal-title":"Front Pediatr"},{"key":"ref65","unstructured":"ICER. Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy. effectiveness and value. (2019). Accessed: January 18, 2025: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_052419.pdf."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.07.033","article-title":"Cost-effectiveness of Nusinersen and universal newborn screening for spinal muscular atrophy","volume":"227","author":"Jalali A","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-effectiveness of Nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020, 227:274-80.e2. 10.1016\/j.jpeds.2020.07.033","journal-title":"J Pediatr"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200624","article-title":"Characterization of adult patients with SMA treated in US hospital settings: a natural history study in the Premier Healthcare Database","volume":"8","author":"Johnson NB","year":"2021","unstructured":"Johnson NB, Proud C, Wassel CL, Dreyfus J, Cochrane T, Paradis AD. Characterization of adult patients with SMA treated in US hospital settings: a natural history study in the Premier Healthcare Database. J Neuromuscul Dis. 2021, 8:569-78. 10.3233\/JND-200624","journal-title":"J Neuromuscul Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2018.09.008","article-title":"Emergency room visits and admission rates of children with neuromuscular disorders: a 10-year experience in a medical center in Taiwan","volume":"60","author":"Kao WT","year":"2019","unstructured":"Kao WT, Tseng YH, Jong YJ, Chen TH. Emergency room visits and admission rates of children with neuromuscular disorders: a 10-year experience in a medical center in Taiwan. Pediatr Neonatol. 2019, 60:405-10. 10.1016\/j.pedneo.2018.09.008","journal-title":"Pediatr Neonatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug C","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, et al.. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016, 11:58. 10.1186\/s13023-016-0424-0","journal-title":"Orphanet J Rare Dis"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2018.11.002","article-title":"Pre-nusinersen hospitalization costs of children with spinal muscular atrophy","volume":"92","author":"Lee M Jr","year":"2019","unstructured":"Lee M Jr, Fran\u00e7a UL, Graham RJ, McManus ML. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. 2019, 92:3-5. 10.1016\/j.pediatrneurol.2018.11.002","journal-title":"Pediatr Neurol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e3182388ad1","article-title":"Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival?","volume":"13","author":"Lemoine TJ","year":"2012","unstructured":"Lemoine TJ, Swoboda KJ, Bratton SL, Holubkov R, Mundorff M, Srivastava R. Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival?. Pediatr Crit Care Med. 2012, 13:e161-5. 10.1097\/PCC.0b013e3182388ad1","journal-title":"Pediatr Crit Care Med"},{"key":"ref72","unstructured":"The Lewin Group. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States final report. (2012). https.\/\/www.mda.org\/sites\/default\/files\/Cost_Illness_Report.pdf."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.25754\/pjp.2021.21315","article-title":"Nusinersen: single-centre real-life experience in type 1 spinal muscular atrophy","volume":"52","author":"Lomba A","year":"2021","unstructured":"Lomba A, Ribeiro JA, Ara\u00fajo H, et al.. Nusinersen: single-centre real-life experience in type 1 spinal muscular atrophy. Port J Pediatr. 2021, 52:281-7. 10.25754\/pjp.2021.21315","journal-title":"Port J Pediatr"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165640","article-title":"The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe","volume":"17","author":"Pe\u00f1a-Longobardo LM","year":"2020","unstructured":"Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E, L\u00f3pez-Bastida J. The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe. Int J Environ Res Public Health. 2020, 17:5640. 10.3390\/ijerph17165640","journal-title":"Int J Environ Res Public Health"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone DC","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al.. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019, 7:1601484. 10.1080\/20016689.2019.1601484","journal-title":"J Mark Access Health Policy"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200610","article-title":"Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada","volume":"8","author":"McMillan HJ","year":"2021","unstructured":"McMillan HJ, Gerber B, Cowling T, et al.. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021, 8:553-68. 10.3233\/JND-200610","journal-title":"J Neuromuscul Dis"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.03641","article-title":"Lifestyle implications of home mechanical insufflation-exsufflation for children with neuromuscular disease and their families","volume":"60","author":"Moran FC","year":"2015","unstructured":"Moran FC, Spittle AJ, Delany C. Lifestyle implications of home mechanical insufflation-exsufflation for children with neuromuscular disease and their families. Respir Care. 2015, 60:967-74. 10.4187\/respcare.03641","journal-title":"Respir Care"},{"key":"ref78","unstructured":"NICE. Nusinersen for treating spinal muscular atrophy. (2019). Accessed. January 21 2025: https:\/\/www.nice.org.uk\/guidance\/ta588\/."},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0b013e318232883a","article-title":"Spinal muscular atrophy type 1: avoidance of hospitalization by respiratory muscle support","volume":"90","author":"Ottonello G","year":"2011","unstructured":"Ottonello G, Mastella C, Franceschi A, et al.. Spinal muscular atrophy type 1: avoidance of hospitalization by respiratory muscle support. Am J Phys Med Rehabil. 2011, 90:895-900. 10.1097\/PHM.0b013e318232883a","journal-title":"Am J Phys Med Rehabil"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17238989","article-title":"The burden of spinal muscular atrophy on informal caregivers","volume":"17","author":"Aranda-Reneo I","year":"2020","unstructured":"Aranda-Reneo I, Pe\u00f1a-Longobardo LM, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano EF, L\u00f3pez-Bastida J. The burden of spinal muscular atrophy on informal caregivers. Int J Environ Res Public Health. 2020, 17:8989. 10.3390\/ijerph17238989","journal-title":"Int J Environ Res Public Health"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.1758","article-title":"PRO22 a real world study investigating the resource use and burden associated with spinal muscular atrophy (SMA) from the perspective of patients and carers in the UK","volume":"23","author":"Rowell J","year":"2020","unstructured":"Rowell J, Vincent SA, Saberian S, Scoto M, Muntoni F. PRO22 a real world study investigating the resource use and burden associated with spinal muscular atrophy (SMA) from the perspective of patients and carers in the UK. Value Health. 2020, 23:S693. 10.1016\/j.jval.2020.08.1758","journal-title":"Value Health"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"Shih ST","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021, 92:1296-304. 10.1136\/jnnp-2021-326344","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.36469\/63185","article-title":"Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy","volume":"6","author":"Tan H","year":"2019","unstructured":"Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J Health Econ Outcomes Res. 2019, 6:185-95. 10.36469\/63185","journal-title":"J Health Econ Outcomes Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.12291","article-title":"Management of children with spinal muscular atrophy type 1 in Australia","volume":"49","author":"Tassie B","year":"2013","unstructured":"Tassie B, Isaacs D, Kilham H, Kerridge I. Management of children with spinal muscular atrophy type 1 in Australia. J Paediatr Child Health. 2013, 49:815-9. 10.1111\/jpc.12291","journal-title":"J Paediatr Child Health"},{"key":"ref85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.879","article-title":"PSY53 - Assessing the real-world hospital economic burden of spinal muscular atrophy (SMA) In France","volume":"20","author":"Tetafort A","year":"2017","unstructured":"Tetafort A, Couray-Targe S, Harmand S, Ansolabehere X, Maurel F, Hammes F. PSY53 - Assessing the real-world hospital economic burden of spinal muscular atrophy (SMA) In France. Value Health. 2017, 20:A553.","journal-title":"Value Health"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala P","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020, 18:41. 10.1186\/s12962-020-00234-8","journal-title":"Cost Eff Resour Alloc"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez S","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, et al.. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019, 37:845-65. 10.1007\/s40273-019-00769-6","journal-title":"Pharmacoeconomics"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel RS","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al.. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018, 28:197-207. 10.1016\/j.nmd.2017.11.004","journal-title":"Neuromuscul Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/346407-global-economic-burden-of-spinal-muscular-atrophy-a-systematic-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T05:13:49Z","timestamp":1742706829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/346407-global-economic-burden-of-spinal-muscular-atrophy-a-systematic-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.81023","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}